Pacira signs partnership with JNJ to expand Zilretta

Arthritis pain

We Are

  • Pacira BioSciences (NASDAQ:PCRX) said it has partnered with Johnson & Johnson MedTech (NYSE:JNJ) to enhance the availability of Zilretta, a treatment designed for knee pain caused by osteoarthritis.
  • This collaboration aims to utilize Johnson & Johnson’s specialized sales team to promote Zilretta

Leave a Reply

Your email address will not be published. Required fields are marked *